Richard D. Brokx

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer

Jacqueline M. Mason, Wei Xin, Graham C. Fletcher et al. · Proceedings of the National Academy of Sciences · 2017 · 133 citations · Full text

ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action

Graham C. Fletcher, Richard D. Brokx, Trisha A. Denny et al. · Molecular Cancer Therapeutics · 2010 · 128 citations

Energetics of Target Peptide Binding by Calmodulin Reveals Different Modes of Binding

Richard D. Brokx, María M. López, Hans J. Vogel et al. · Journal of Biological Chemistry · 2001 · 116 citations · Full text

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

Yong Liu, Radoslaw S. Laufer, Narendra Kumar Patel et al. · ACS Medicinal Chemistry Letters · 2016 · 78 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Drug Target +14

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Zachary Veitch, David W. Cescon, Trisha A. Denny et al. · British Journal of Cancer · 2019 · 66 citations · Full text